<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Beta-adrenoceptor blocking drugs; Beta-blockers see Beta-adrenoceptor blocking drugs; Labetalol; Celiprolol; Carvedilol; Nebivolol; Antihypertensives: beta-blockers; Hypertension: beta-blockers; Beta-adrenoceptor blocking drugs: hypertension; Phaeochromocytoma; Beta-adrenoceptor blocking drugs: angina; Angina: management: beta-blockers; Beta-adrenoceptor blocking drugs: myocardial infarction; Myocardial infarction: management: beta-blockers; Beta-adrenoceptor blocking drugs: arrhythmias; Arrhythmias: beta-blockers; Esmolol; Sotalol: cardiovascular; Beta-adrenoceptor blocking drugs: heart failure; Heart failure: beta-blockers; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers" /><meta name="IX" content="Beta-adrenoceptor blocking drugs; Labetalol; Celiprolol; Carvedilol; Nebivolol; Antihypertensives: beta-blockers; Hypertension: beta-blockers; Beta-adrenoceptor blocking drugs: hypertension; Phaeochromocytoma; Beta-adrenoceptor blocking drugs: angina; Angina: management: beta-blockers; Beta-adrenoceptor blocking drugs: myocardial infarction; Myocardial infarction: management: beta-blockers; Beta-adrenoceptor blocking drugs: arrhythmias; Arrhythmias: beta-blockers; Esmolol; Sotalol: cardiovascular; Beta-adrenoceptor blocking drugs: heart failure; Heart failure: beta-blockers; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers" /><meta name="IXN" content="Beta-blockers see Beta-adrenoceptor blocking drugs" /><title>2.4 Beta-adrenoceptor blocking drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP934-beta-adrenoceptor-blocking-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP934-beta-adrenoceptor-blocking-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP934-beta-adrenoceptor-blocking-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP928-lidocaine-hydrochloride.htm" title="Previous: LIDOCAINE HYDROCHLORIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP944-propranolol-hydrochloride.htm" title="Next: PROPRANOLOL HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>2.4 </span>Beta-adrenoceptor blocking drugs</h1><?highlighter on?><div id="pC" class="jN"><p>Beta-adrenoceptor blocking drugs (beta-blockers) block the beta-adrenoceptors in the heart, peripheral vasculature, bronchi, pancreas, and liver.</p> <p>Many beta-blockers are now available and in general they are all equally effective. There are, however, differences between them, which may affect choice in treating particular diseases or individual patients.</p> <p>Intrinsic sympathomimetic activity (ISA, partial agonist activity) represents the capacity of beta-blockers to stimulate as well as to block adrenergic receptors. <strong>Oxprenolol</strong>, <strong>pindolol</strong>, <strong>acebutolol</strong>, and <strong>celiprolol</strong> have intrinsic sympathomimetic activity; they tend to cause less bradycardia than the other beta-blockers and may also cause less coldness of the extremities. </p> <p>Some beta-blockers are lipid soluble and some are water soluble. <strong>Atenolol</strong>, <strong>celiprolol</strong>, <strong>nadolol</strong>, and <strong>sotalol</strong> are the most water-soluble; they are less likely to enter the brain, and may therefore cause less sleep disturbance and nightmares. Water-soluble beta-blockers are excreted by the kidneys and dosage reduction is often necessary in renal impairment. </p> <p>Beta-blockers with a relatively short duration of action have to be given two or three times daily. Many of these are, however, available in modified-release formulations so that administration once daily is adequate for hypertension. For angina twice-daily treatment may sometimes be needed even with a modified-release formulation. Some beta-blockers, such as atenolol, bisoprolol, carvedilol, celiprolol, and nadolol, have an intrinsically longer duration of action and need to be given only once daily.</p> <p>Beta-blockers slow the heart and can depress the myocardium; they are contra-indicated in patients with second- or third-degree heart block. Beta-blockers should also be avoided in patients with worsening unstable heart failure; care is required when initiating a beta-blocker in those with stable heart failure (see also <a title="topic: Heart failure" href="PHP1123-heart-failure.htm">section 2.5.5</a>). <strong>Sotalol</strong> may prolong the QT interval, and it occasionally causes life-threatening ventricular arrhythmias (<strong>important:</strong> particular care is required to avoid hypokalaemia in patients taking sotalol).</p> <p><strong>Labetalol</strong>, <strong>celiprolol</strong>, <strong>carvedilol</strong>, and <strong>nebivolol</strong> are beta-blockers that have, in addition, an arteriolar vasodilating action, by diverse mechanisms, and thus lower peripheral resistance. There is no evidence that these drugs have important advantages over other beta-blockers in the treatment of hypertension.</p> <p id="PHP937">Beta-blockers can precipitate bronchospasm and should therefore usually be avoided in patients with a history of asthma. When there is no suitable alternative, it may be necessary for a patient with well-controlled asthma, or chronic obstructive pulmonary disease (without significant reversible airways obstruction), to receive treatment with a beta-blocker for a co-existing condition (e.g. heart failure or following myocardial infarction). In this situation, a cardioselective beta-blocker should be selected and initiated at a low dose by a specialist; the patient should be closely monitored for adverse effects. <strong>Atenolol</strong>, <strong>bisoprolol</strong>, <strong>metoprolol</strong>, <strong>nebivolol</strong>, and (to a lesser extent) <strong>acebutolol</strong>, have less effect on the beta<sub>2</sub> (bronchial) receptors and are, therefore, relatively <em>cardioselective</em>, but they are not <em>cardiospecific</em>. They have a lesser effect on airways resistance but are not free of this side-effect.</p> <p>Beta-blockers are also associated with fatigue, coldness of the extremities (may be less common with those with ISA, see above), and sleep disturbances with nightmares (may be less common with the water-soluble beta-blockers, see above). </p> <p>Beta-blockers can affect carbohydrate metabolism, causing hypoglycaemia or hyperglycaemia in patients with or without diabetes; they can also interfere with metabolic and autonomic responses to hypoglycaemia, thereby masking symptoms such as tachycardia. However, beta-blockers are not contra-indicated in diabetes, although the cardioselective beta-blockers (see above) may be preferred. Beta-blockers should be avoided altogether in those with frequent episodes of hypoglycaemia. Beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or in those at high risk of developing diabetes.</p> <div id="PHP938"><h2>Pregnancy</h2><p>Beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia; the risk is greater in severe hypertension. The use of labetalol in maternal hypertension is not known to be harmful, except possibly in the first trimester. Information on the safety of carvedilol during pregnancy is lacking. If beta-blockers are used close to delivery, infants should be monitored for signs of beta-blockade (and alpha-blockade with labetalol or carvedilol). For the treatment of hypertension in pregnancy, see <a title="BNF:target-block: Hypertension in pregnancy" href="PHP1034-hypertension-and-heart-failure.htm#PHP1038">section 2.5</a>.</p></div> <div id="PHP939"><h2>Breast-feeding</h2><p>Infants should be monitored as there is a risk of possible toxicity due to beta-blockade (and alpha-blockade with labetalol or carvedilol), but the amount of most beta-blockers present in milk is too small to affect infants. Acebutolol, atenolol, nadolol, and sotalol are present in milk in greater amounts than other beta-blockers. The manufacturers of celiprolol, esmolol, and nebivolol advise avoidance if breast-feeding.</p></div> <div><h2>Hypertension</h2><p>The mode of action of beta-blockers in hypertension is not understood, but they reduce cardiac output, alter baroceptor reflex sensitivity, and block peripheral adrenoceptors. Some beta-blockers depress plasma renin secretion. It is possible that a central effect may also partly explain their mode of action.</p><p>Beta-blockers are effective for reducing blood pressure but other antihypertensives (<a title="section: Drugs affecting the renin-angiotensin system and some other antihypertensive drugs" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>) are usually more effective for reducing the incidence of stroke, myocardial infarction, and cardiovascular mortality, especially in the elderly. Other antihypertensives are therefore preferred for routine initial treatment of uncomplicated hypertension.</p><p>In general, the dose of a beta-blocker does not have to be high; for example, atenolol is given in a dose of 25–50 mg daily and it is rarely necessary to increase the dose to 100 mg.</p> <p id="PHP940">Beta-blockers can be used to control the pulse rate in patients with <em>phaeochromocytoma</em> (<a title="monograph-family: Phaeochromocytoma" href="PHP1116-phaeochromocytoma.htm">section 2.5.4</a>). However, they should never be used alone as beta-blockade without concurrent alpha-blockade may lead to a hypertensive crisis. For this reason phenoxybenzamine should always be used together with the beta-blocker.</p> </div> <div><h2>Angina</h2><p>By reducing cardiac work beta-blockers improve exercise tolerance and relieve symptoms in patients with <em>angina</em> (for further details on the management of stable angina and acute coronary syndromes, see <a title="BNF:sub-section: Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>). As with hypertension there is no good evidence of the superiority of any one drug, although occasionally a patient will respond better to one beta-blocker than to another. There is some evidence that sudden withdrawal may cause an exacerbation of angina and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped. There is a risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischaemic heart disease (<strong>important</strong>: see VERAPAMIL <a title=" Calcium-channel blockers" href="PHP1309-calcium-channel-blockers.htm">section 2.6.2</a>).</p></div> <div><h2>Myocardial infarction</h2><p>For advice on the management of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, see <a title=" Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>. Several studies have shown that some beta-blockers can reduce the recurrence rate of <em>myocardial infarction</em>. However, uncontrolled heart failure, hypotension, bradyarrhythmias, and obstructive airways disease render beta-blockers unsuitable in some patients following a myocardial infarction. <strong>Atenolol</strong> and <strong>metoprolol</strong> may reduce early mortality after intravenous and subsequent oral administration in the acute phase, while <strong>acebutolol</strong>, <strong>metoprolol</strong>, <strong>propranolol</strong>, and <strong>timolol</strong> have protective value when started in the early convalescent phase. The evidence relating to other beta-blockers is less convincing; some have not been tested in trials of secondary prevention. Sudden cessation of a beta-blocker can cause a rebound worsening of myocardial ischaemia.</p></div> <div id="PHP941"><h2>Arrhythmias</h2><p>Beta-blockers act as <em>anti-arrhythmic drugs </em>principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. They can be used in conjunction with digoxin to control the ventricular response in atrial fibrillation, especially in patients with thyrotoxicosis. Beta-blockers are also useful in the management of supraventricular tachycardias, and are used to control those following myocardial infarction (see above). </p><p><strong>Esmolol</strong> is a relatively cardioselective beta-blocker with a very short duration of action, used intravenously for the short-term treatment of supraventricular arrhythmias, sinus tachycardia, or hypertension, particularly in the peri-operative period. It may also be used in other situations, such as acute myocardial infarction, when sustained beta-blockade might be hazardous.</p> <p id="PHP942"><strong>Sotalol</strong>, a non-cardioselective beta-blocker with additional class III anti-arrhythmic activity, is used for prophylaxis in paroxysmal supraventricular arrhythmias. It also suppresses ventricular ectopic beats and non-sustained ventricular tachycardia. It has been shown to be more effective than lidocaine in the termination of spontaneous sustained ventricular tachycardia due to coronary disease or cardiomyopathy. However, it may induce torsade de pointes in susceptible patients.</p> </div> <div><h2>Heart failure</h2><p>Beta-blockers may produce benefit in heart failure by blocking sympathetic activity. <strong>Bisoprolol</strong> and <strong>carvedilol</strong> reduce mortality in any grade of stable heart failure; <strong>nebivolol</strong> is licensed for stable mild to moderate heart failure in patients over 70 years. Treatment should be initiated by those experienced in the management of heart failure (<a title=" Drugs affecting the renin-angiotensin system" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">section 2.5.5</a>).</p></div> <div id="PHP943"><h2>Thyrotoxicosis</h2><p>Beta-blockers are used in pre-operative preparation for thyroidectomy. Administration of propranolol can reverse clinical symptoms of <em>thyrotoxicosis</em> within 4 days. Routine tests of increased thyroid function remain unaltered. The thyroid gland is rendered less vascular thus making surgery easier (<a title=" Antithyroid drugs" href="PHP4309-antithyroid-drugs.htm">section 6.2.2</a>).</p></div> <div><h2>Other uses</h2><p>Beta-blockers have been used to alleviate some symptoms of <em>anxiety</em>; probably patients with palpitation, tremor, and tachycardia respond best (see also <a title=" Anxiolytics" href="PHP2151-anxiolytics.htm">section 4.1.2</a> and <a title=" Drugs used in essential tremor, chorea, tics, and related disorders" href="PHP3157-drugs-used-in-essential-tremor-chorea-tics-and-related-disorders.htm">section 4.9.3</a>). Beta-blockers are also used in the <em>prophylaxis of migraine</em> (<a title=" Prophylaxis of migraine" href="PHP2872-prophylaxis-of-migraine.htm">section 4.7.4.2</a>). Betaxolol, carteolol, levobunolol, and timolol are used topically in <em>glaucoma</em> (<a title=" Treatment of glaucoma" href="PHP6952-treatment-of-glaucoma.htm">section 11.6</a>).</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP944-propranolol-hydrochloride"><a href="PHP944-propranolol-hydrochloride.htm" title="PROPRANOLOL HYDROCHLORIDE">PROPRANOLOL HYDROCHLORIDE</a></li><li id="_PHP952-acebutolol"><a href="PHP952-acebutolol.htm" title="ACEBUTOLOL">ACEBUTOLOL</a></li><li id="_PHP954-atenolol"><a href="PHP954-atenolol.htm" title="ATENOLOL">ATENOLOL</a></li><li id="_PHP971-bisoprolol-fumarate"><a href="PHP971-bisoprolol-fumarate.htm" title="BISOPROLOL FUMARATE">BISOPROLOL FUMARATE</a></li><li id="_PHP975-carvedilol"><a href="PHP975-carvedilol.htm" title="CARVEDILOL">CARVEDILOL</a></li><li id="_PHP978-celiprolol-hydrochloride"><a href="PHP978-celiprolol-hydrochloride.htm" title="CELIPROLOL HYDROCHLORIDE">CELIPROLOL HYDROCHLORIDE</a></li><li id="_PHP983-co-tenidone"><a href="PHP983-co-tenidone.htm" title="CO-TENIDONE">CO-TENIDONE</a></li><li id="_PHP987-esmolol-hydrochloride"><a href="PHP987-esmolol-hydrochloride.htm" title="ESMOLOL HYDROCHLORIDE">ESMOLOL HYDROCHLORIDE</a></li><li id="_PHP989-labetalol-hydrochloride"><a href="PHP989-labetalol-hydrochloride.htm" title="LABETALOL HYDROCHLORIDE">LABETALOL HYDROCHLORIDE</a></li><li id="_PHP993-metoprolol-tartrate"><a href="PHP993-metoprolol-tartrate.htm" title="METOPROLOL TARTRATE">METOPROLOL TARTRATE</a></li><li id="_PHP1001-nadolol"><a href="PHP1001-nadolol.htm" title="NADOLOL">NADOLOL</a></li><li id="_PHP1003-nebivolol"><a href="PHP1003-nebivolol.htm" title="NEBIVOLOL">NEBIVOLOL</a></li><li id="_PHP1006-oxprenolol-hydrochloride"><a href="PHP1006-oxprenolol-hydrochloride.htm" title="OXPRENOLOL HYDROCHLORIDE">OXPRENOLOL HYDROCHLORIDE</a></li><li id="_PHP1013-pindolol"><a href="PHP1013-pindolol.htm" title="PINDOLOL">PINDOLOL</a></li><li id="_PHP1020-sotalol-hydrochloride"><a href="PHP1020-sotalol-hydrochloride.htm" title="SOTALOL HYDROCHLORIDE">SOTALOL HYDROCHLORIDE</a></li><li id="_PHP1025-timolol-maleate"><a href="PHP1025-timolol-maleate.htm" title="TIMOLOL MALEATE">TIMOLOL MALEATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP928-lidocaine-hydrochloride.htm">Previous: LIDOCAINE HYDROCHLORIDE</a> | <a class="top" href="PHP934-beta-adrenoceptor-blocking-drugs.htm#">Top</a> | <a accesskey="]" href="PHP944-propranolol-hydrochloride.htm">Next: PROPRANOLOL HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>